RLMD NASDAQ
Relmada Therapeutics, Inc.
1W: +2.2%
1M: -15.7%
3M: -38.2%
YTD: -26.1%
1Y: +46.1%
3Y: +316.8%
5Y: -30.1%
$3.17
-0.06 (-1.70%)
Weekly Expected Move ±7.8%
$3
$3
$3
$4
$4
Credit Risk of going bust: not rated Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Not rated: no debt. Altman Z'' 10.92.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$1.7M
Congress—
ETF Holdings—
Key Statistics
Market Cap$344.5M
52W Range2.15-8
Volume775,829
Avg Volume1,639,327
Beta0.45
Dividend—
Analyst Ratings
Company Info
CEOSergio Traversa
Employees17
SectorHealthcare
IndustryBiotechnology
IPO Date2014-06-20
Websiterelmada.com
2222 Ponce de Leon Blvd.
Coral Gables, FL 33134
US
Coral Gables, FL 33134
US
786 629 1376
About Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive GABAergic activity. The company has an agreement with Asarina Pharma AB and Trigone. Relmada Therapeutics, Inc. was founded in 2004 and is headquartered in Coral Gables, Florida.
Latest News
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Stock Has Consensus Target Price of $12.00
812,059 Shares in Relmada Therapeutics, Inc. $RLMD Purchased by Bank of America Corp DE
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)
Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Shenouda Maged | P-Purchase | 79,800 | $4.25 | 2026-09-10 |
| TRAVERSA SERGIO | P-Purchase | 100,000 | $4.10 | 2026-09-10 |
| Shenouda Maged | P-Purchase | 120,200 | $4.20 | 2026-09-09 |
| TRAVERSA SERGIO | P-Purchase | 100,000 | $4.18 | 2026-09-09 |
| TRAVERSA SERGIO | P-Purchase | 27,500 | $4.12 | 2025-12-15 |